Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Children With Recurrent/Refractory Solid Tumors and Leukemias
NCT01154816Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Feb 2011
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of alisertib in neuroblastoma, rhabdomyosarcoma (RMS), osteosarcoma (OS) and 9 more (12 arms), sponsored by Children's Oncology Group. Primary endpoint: Objective Response Rate. Started Feb 2011; status: completed.
02
Drugs
alisertib
03
Conditions
neuroblastomarhabdomyosarcoma (RMS)osteosarcoma (OS)Ewing sarcomaPeripheral Primitive Neuroectodermal Tumor (pPNET)
Beyond the preview
Go deeper on NCT01154816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154816.